{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:10:16Z","timestamp":1787739016903,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gdansk University","award":["71-1212"],"award-info":[{"award-number":["71-1212"]}]},{"name":"Universit\u00e4t Augsburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to investigate very early radiographic PSMA PET response after one cycle of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA I&amp;T radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) and to assess its role in predicting overall response and survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study enrolled 40 mCRPC patients who were treated with a median of 3 (2\u20139) [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA I&amp;T RLT cycles. Biochemical response was based on the relative change of serum PSA according to PCWG3 criteria, while radiographic response referred to the relative change of PSMA-derived total viable tumor volumes expressed as total lesion PSMA (TLP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After one cycle of RLT, biochemical partial response (PR) was seen in 8\/40 (20.0%), stable disease (SD) in 22\/40 (55.0%), and progressive disease (PD) in 10\/40 (25%) patients. In PSMA PET, very early molecular PR was observed in 12 (30.0%), SD in 19 (47.5%), and PD in 9 (22.5%) subjects. The PSA and TLP nadir were achieved after a median of 1 (1\u20135) and 2 (1\u20136) cycles, respectively. Nineteen (47.5%) patients showed overall biochemical PR, 11 (27.5%) had SD, and 10 (25%) experienced PD. In PSMA-directed PET, 4 patients experienced molecular complete response (CR), 24 (60.0%) had PR, 4 (10.0%) SD, and 8 (20.0%) PD. Early biochemical or radiographic response was not associated with longer overall survival (OS). Overall biochemical responders had a nearly significantly longer median OS (22.7\u00a0months) than non-responders (14.4\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.08). Early PSA progression was associated with shorter OS (12.2\u00a0months), compared to biochemical SD\/PR (18.7\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.09).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this retrospective cohort, there was no association between early PSMA PET radiographic response and overall survival; hence, treatment should not be prematurely discontinued. In contrast, early PSA progression after one cycle of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA I&amp;T RLT was an indicator of overall progression and poor clinical outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06326-w","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T03:21:53Z","timestamp":1689909713000},"page":"3765-3776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&amp;T radioligand therapy in metastatic castration-resistant prostate cancer patients"],"prefix":"10.1007","volume":"50","author":[{"given":"Wojciech","family":"Cytawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart\u0142omiej","family":"Tomasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Xaver","family":"Weinzierl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Bley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schirbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-2207","authenticated-orcid":false,"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"6326_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.005","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005.","journal-title":"Eur Urol"},{"key":"6326_CR2","unstructured":"Leslie SW, Soon-Sutton TL, R I A, Sajjad H, Siref LE. Prostate Cancer. 2023 May 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"6326_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv257","author":"S Gillessen","year":"2015","unstructured":"Gillessen S, Omlin A. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC). Ann Oncol. 2015. https:\/\/doi.org\/10.1093\/annonc\/mdv257.","journal-title":"Ann Oncol"},{"key":"6326_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14828","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019. https:\/\/doi.org\/10.1111\/bju.14828.","journal-title":"BJU Int"},{"key":"6326_CR5","doi-asserted-by":"publisher","unstructured":"Grewal K, Grewal K. Anticancer Research. 2021; https:\/\/doi.org\/10.21873\/anticanres.14807","DOI":"10.21873\/anticanres.14807"},{"key":"6326_CR6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.168443","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016. https:\/\/doi.org\/10.2967\/jnumed.115.168443.","journal-title":"J Nucl Med"},{"key":"6326_CR7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/jnumed.116.183194.","journal-title":"J Nucl Med"},{"key":"6326_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"6326_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J. Lutetium-177-PSMA-617 for metastatic castrationresistant prostate cancer. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"6326_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05864-z","author":"S Fanti","year":"2022","unstructured":"Fanti S, Kunikowska J. EANM-EAU consensus on PSMA PET\/CT in respect to radioligand therapy ([177Lu]Lu-PSMA). Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-022-05864-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"6326_CR12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193581","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA. Initial experience with volumetric 68Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/jnumed.117.193581.","journal-title":"J Nucl Med"},{"key":"6326_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4042-z","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M. 68Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018. https:\/\/doi.org\/10.1007\/s00259-018-4042-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR14","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.649","author":"J-H Liang","year":"2019","unstructured":"Liang J-H, Zhang Y-P. Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat. 2019. https:\/\/doi.org\/10.4143\/crt.2018.649.","journal-title":"Cancer Res Treat"},{"key":"6326_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4173-2","author":"D Albano","year":"2019","unstructured":"Albano D, Re A. Prognostic role of \u0394MTV and \u0394TLG in Burkitt lymphoma. Ann Nucl Med. 2019. https:\/\/doi.org\/10.1007\/s00259-018-4173-2.","journal-title":"Ann Nucl Med"},{"key":"6326_CR16","doi-asserted-by":"publisher","unstructured":"Gafita A, Rauscher I. Novel framework for treatment response evaluation using PSMA-PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2020; https:\/\/doi.org\/10.2967\/jnumed.121.263072","DOI":"10.2967\/jnumed.121.263072"},{"key":"6326_CR17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.086751","author":"SM Hillier","year":"2011","unstructured":"Hillier SM, Kern AM. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011. https:\/\/doi.org\/10.2967\/jnumed.110.086751.","journal-title":"J Nucl Med"},{"key":"6326_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"6326_CR19","doi-asserted-by":"publisher","unstructured":"Cytawa W, Hartrampf P. PSMA Theranostics: A \u201cMUST HAVE\u201d IN EVERY PROSTATE CANCER Center. Illustration of two clinical cases and review of the literature. Clin Genitourin Cancer. 2021; https:\/\/doi.org\/10.1016\/j.clgc.2021.03.008","DOI":"10.1016\/j.clgc.2021.03.008"},{"key":"6326_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3877-z","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, B\u00f6geman M. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018. https:\/\/doi.org\/10.1007\/s00259-017-3877-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05594-8","author":"F Rosar","year":"2022","unstructured":"Rosar F, Wenner F. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-021-05594-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR22","doi-asserted-by":"crossref","unstructured":"Fendler WP, Kratochwil C. Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016; German. https:\/\/pubmed.ncbi.nlm.nih.gov\/27350005\/. Accessed: 28 Nov 2022.","DOI":"10.1055\/s-0037-1616480"},{"key":"6326_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05853-2","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Seitz A. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-022-05853-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030647","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl FX. Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030647.","journal-title":"Cancers (Basel)"},{"key":"6326_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05910-w","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Bundschuh RA. mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-022-05910-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05744-6","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl FX. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-022-05744-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biology11050660","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Krebs M. Reduced segmentation of lesions is comparable to whole-body segmentation for response assessment by PSMA PET\/CT: initial experience with the keyhole approach. Biology (Basel). 2022. https:\/\/doi.org\/10.3390\/biology11050660.","journal-title":"Biology (Basel)"},{"key":"6326_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24414","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl FX. Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy. Prostate. 2022. https:\/\/doi.org\/10.1002\/pros.24414.","journal-title":"Prostate"},{"key":"6326_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04524-z","author":"W Cytawa","year":"2020","unstructured":"Cytawa W, Seitz AK. 68Ga-PSMA I&T PET\/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-019-04524-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04723-z","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04723-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4236-4","author":"B Grubm\u00fcller","year":"2019","unstructured":"Grubm\u00fcller B, Senn D. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019. https:\/\/doi.org\/10.1007\/s00259-018-4236-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0051862.","journal-title":"PLoS ONE"},{"key":"6326_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05525-7","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-021-05525-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.240242","author":"A Gafita","year":"2020","unstructured":"Gafita A, Heck MM. Early prostate-specific antigen changes and clinical outcome after 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020. https:\/\/doi.org\/10.2967\/jnumed.119.240242.","journal-title":"J Nucl Med"},{"key":"6326_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1576-0","author":"GJR Cook","year":"2011","unstructured":"Cook GJR, Venkitaraman R. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging. 2011. https:\/\/doi.org\/10.1007\/s00259-010-1576-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6326_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2797","author":"JE Mortimer","year":"2001","unstructured":"Mortimer JE, Dehdashti F. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001. https:\/\/doi.org\/10.1200\/JCO.2001.19.11.2797.","journal-title":"J Clin Oncol"},{"key":"6326_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920987654","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Poti G. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. Ther Adv Med Oncol. 2021. https:\/\/doi.org\/10.1177\/1758835920987654.","journal-title":"Ther Adv Med Oncol"},{"key":"6326_CR38","doi-asserted-by":"publisher","unstructured":"Gaertner FC, Halabi K. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017; https:\/\/doi.org\/10.18632\/oncotarget.19049","DOI":"10.18632\/oncotarget.19049"},{"key":"6326_CR39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261906","author":"A Gafita","year":"2022","unstructured":"Gafita A, Wang H. Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality? J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.121.261906.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06326-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T21:01:55Z","timestamp":1696366915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06326-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6326"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06326-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}